Rimonabant-induced catatonia in schizophrenia: A case report.

CONCLUSIONS

Patients with psychiatric illness have higher rates of mortality and medical co-morbidity related to increased rates of diabetes mellitus and cardiovascular disease. Rimonabant, a cannabinoid receptor (CB1) antagonist, is an anti-obesity agent and decreases risk for metabolic syndrome. Though there are reports of rimonabant associated with adverse psychiatric events like depression, rimonabant-induced catatonia is not reported. In this first time report, we describe a patient with schizophrenia developing catatonia possibly due to rimonabant.: